InsidersTradesSigma
Track the AIkido Pharma Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, AIkido Pharma Inc. has recorded 39 insider filings. The latest transaction was disclosed on 21 December 2022 (Acquisition). Among the most active insiders: Wool Kyle Michael. Every trade is accessible without an account.
39
Insider Decl.
n/a
Thresholds
€2m
25 ops.
Buy Volume
n/a
n/a
Sell Volume
44Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 December 2022
Declarations39 total
5,000 shares@ US$3.5931.6% of flowCommon StockSEC:0001213900-22-081779:0
Canonical exit: 19 Mar 2023 (T+90)
5,000 shares@ US$3.7051.6% of flowCommon StockSEC:0001213900-22-081468:0
Canonical exit: 16 Mar 2023 (T+90)
5,000 shares@ US$3.6871.6% of flowCommon StockSEC:0001213900-22-080685:0
Canonical exit: 15 Mar 2023 (T+90)
4,500 shares@ US$3.691.5% of flowCommon StockSEC:0001213900-22-080303:0
Canonical exit: 14 Mar 2023 (T+90)
4,500 shares@ US$3.691.6% of flowCommon StockSEC:0001213900-22-080305:0
Canonical exit: 14 Mar 2023 (T+90)
5,000 shares@ US$3.6971.8% of flowCommon StockSEC:0001213900-22-079914:0
Canonical exit: 13 Mar 2023 (T+90)
5,000 shares@ US$3.6971.6% of flowCommon StockSEC:0001213900-22-079913:0
Canonical exit: 13 Mar 2023 (T+90)
5,000 shares@ US$3.6251.6% of flowCommon StockSEC:0001213900-22-079628:0
Canonical exit: 12 Mar 2023 (T+90)
5,000 shares@ US$3.6251.7% of flowCommon StockSEC:0001213900-22-079627:0
Canonical exit: 12 Mar 2023 (T+90)
5,000 shares@ US$3.6831.8% of flowCommon StockSEC:0001213900-22-079304:0
Canonical exit: 9 Mar 2023 (T+90)
5,000 shares@ US$3.6831.6% of flowCommon StockSEC:0001213900-22-079303:0
Canonical exit: 9 Mar 2023 (T+90)
5,000 shares@ US$3.5621.6% of flowCommon StockSEC:0001213900-22-078919:0
Canonical exit: 8 Mar 2023 (T+90)
5,000 shares@ US$3.5621.7% of flowCommon StockSEC:0001213900-22-078918:0
Canonical exit: 8 Mar 2023 (T+90)
5,000 shares@ US$3.47661.5% of flowCommon StockSEC:0001213900-22-078601:0
Canonical exit: 7 Mar 2023 (T+90)
5,000 shares@ US$3.4761.7% of flowCommon StockSEC:0001213900-22-078489:0
Canonical exit: 7 Mar 2023 (T+90)
3,559 shares@ US$6.5432.2% of flowCommon StockSEC:0001213900-22-056768:0
Canonical exit: 15 Dec 2022 (T+90)
1,477 shares@ US$6.1160.8% of flowCommon StockSEC:0001213900-22-056374:0
Canonical exit: 13 Dec 2022 (T+90)
23,712 shares@ US$6.32314.0% of flowCommon StockSEC:0001213900-22-056071:0
Canonical exit: 12 Dec 2022 (T+90)
24,957 shares@ US$6.32316.0% of flowCommon StockSEC:0001213900-22-056072:0
Canonical exit: 12 Dec 2022 (T+90)
38,208 shares@ US$6.32524.2% of flowCommon StockSEC:0001213900-22-055809:0
Canonical exit: 11 Dec 2022 (T+90)
36,298 shares@ US$6.32521.1% of flowCommon StockSEC:0001213900-22-055810:0
Canonical exit: 11 Dec 2022 (T+90)
8,000 shares@ US$6.0056.5% of flowCommon StockSEC:0001213900-22-052355:0
25 of 39 declarations
关于 AIkido Pharma Inc.
AIkido Pharma Inc.（股票代码：AIKI）是一家在美国纳斯达克市场上市的生物技术公司。对于法国、比利时或瑞士的法语投资者而言，它应被视为一家小型、高风险的生物技术公司，其投资案例历来与药物发现和早期开发而非商业销售相关。该公司最初成立于 1967 年，这赋予了它悠久的企业历史，尽管其战略定位随时间发生了实质性变化。公开文件和公司资料显示，自 2017 年以来，该公司一直作为一家生物技术开发商运营，专注于小分子治疗项目，重点是肿瘤学，有时也包括抗病毒研究。([sec.gov](https://www.sec.gov/Archives/edgar/data/12239/000121390021017738/f10k2020_aikidopharma.htm?utm_source=openai)) 从科学角度看，AIkido 描述了一个围绕从大学和研究人员那里获得专利技术许可而建立的管线，并提及与德克萨斯大学奥斯汀分校、马里兰大学巴尔的摩分校和维克森林大学的合作。其披露的治疗重点包括胰腺癌、急性髓系白血病 (AML)、急性淋巴细胞白血病 (ALL) 和广谱抗病毒平台。该公司还提到了前列腺癌和胰腺癌的临床前工作。这些都是重要的数据点，但应将其解释为处于开发阶段的资产，而非经过验证的商业产品。([sec.gov](https://www.sec.gov/Archives/edgar/data/12239/000121390021017738/f10k2020_aikidopharma.htm?utm_source=openai)) 从竞争角度看，AIkido 最好被理解为一家以管线为驱动的生物技术公司，而非多元化的制药公司。这意味着其市场地位取决于临床前或临床概念验证的实力、知识产权、许可条款和融资能力。实际上，该股的行为更像是未来临床成功的研发期权，而非拥有经常性产品收入的成熟医疗保健特许经营权。([sec.gov](https://www.sec.gov/Archives/edgar/data/12239/000121390021017738/f10k2020_aikidopharma.htm?utm_source=openai)) 从地理位置上看，该公司总部位于美国。其网站列出的地址是纽约州纽约市洛克菲勒广场一号，而 SEC 文件则将发行人标识为特拉华州公司。最近的文件还提到了纽约的研发空间和新泽西州泽西市的东海岸总部。对于国际投资者而言，这意味着该名称牢固地嵌入美国监管环境，并受纳斯达克披露标准和 SEC 报告要求的约束。([aikidopharma.com](https://www.aikidopharma.com/about?utm_source=openai)) 最近的公开新闻更多地集中在融资、公司结构和监管备案上，而非重大的商业里程碑。这使得 Form 4 内部人交易监控尤为重要，因为内部人活动可以提供有关管理层情绪、资本结构压力或即将到来的公司催化剂的线索。总的来说，AIKI 仍然是一种投机性的美国生物技术证券，其估值可能由临床新闻流、许可进展和资产负债表发展而非当前的经营收益驱动。([sec.gov](https://www.sec.gov/Archives/edgar/data/12239/000121390022010395/ea156372ex99-1_aiki.htm?utm_source=openai))
